GET THE APP

Development and validation of stability indicating method for the estimation of pazopanib hydrochloride in pharmaceutical dosage forms by RP-HPLC | Abstract
Scholars Research Library

Scholars Research Library

A-Z Journals

+44 7389645282

Der Pharmacia Lettre

Abstract

Development and validation of stability indicating method for the estimation of pazopanib hydrochloride in pharmaceutical dosage forms by RP-HPLC

Author(s): Renju Prabhakaran1, Janakiraman K.2 and Jyoti Harindran3

A stability indicating reverse phase high performance liquid chromatography (RP-HPLC) method was developed and validated in pharmaceutical dosage form using Inertsil C18 (250mm × 4.6mm, 5m) column in isocratic mode with a mobile phase consisting of 0.1% ortho phosphoric acid and acetonitrile in the ratio 55:45 (%v/v). The detection was monitored using PDA detector at 269nm with a flow rate of 1mL/min and the column oven temperature was maintained at 30ºC. The retention time was found to be 5.1mins. A good linear response was observed in the concentration range of 25μg/mL – 150μg/mL with a correlation coefficient of 0.999. The method was validated as per ICH guidelines. Pazopanib hydrochloride was subjected to stress conditions including acidic, alkaline, oxidation, photolysis, thermal and neutral degradation, and the results showed that the net degradation was found to be within the limits.